期刊文献+

Celastrol induces caspase-dependent apoptosis of hepatocellular carcinoma cells by suppression of mammalian target of rapamycin 被引量:1

原文传递
导出
摘要 OBJECTIVE: To investigate the efficacy of celastrol treatment of hepatocellular carcinoma(HCC) cells in vitro and in vivo and to propose a mechanism of action.METHODS: A human Hep G2 liver cancer cell line and a xenograft tumor model were used to investigate the effects of celastrol on HCC in vitro and in vivo. A CCK-8 kit was used to detect cell viability.Flow cytometry and terminal-deoxynucleoitidyl transferase mediated nick end labeling staining were used to detect apoptosis. Western blotting and immunohistochemistry were used to detect the expression of cleaved-caspase-3, cleaved-caspase-8, cleaved-caspase-9, cleaved-PARP, mammalian target of rapamycin(mTOR), and p-mTOR. Hematoxylin-eosin staining was used to observe the tissue morphology.RESULTS: Celastrol decreased the viability of Hep G2 cells and induced apoptosis. Western blot assays indicated that celastrol up-regulated cleaved-caspase-3, cleaved-caspase-8, cleaved-caspase-9, and cleaved-PARP by inhibiting the phosphorylation of mTOR in Hep G2 cells. Moreover,celastrol inhibited the tumor growth in a xenograft model. Celastrol also induced caspase-dependent apoptosis(up-regulation of cleaved-caspase-3,-8,-9, and cleaved-PARP) and inhibited the activation of mTOR in vivo.CONCLUSION: Celastrol induces caspase-dependent apoptosis in HCC cells by inhibiting the activation of mTOR.
出处 《Journal of Traditional Chinese Medicine》 SCIE CSCD 2021年第3期381-389,共9页 中医杂志(英文版)
基金 Supported by Nanjing Medical Science and technique Development Foundation (No.QRX17194)。
  • 相关文献

二级参考文献17

  • 1Ann-Lii Cheng,Yoon-Koo Kang,Zhendong Chen,Chao-Jung Tsao,Shukui Qin,Jun Suk Kim,Rongcheng Luo,Jifeng Feng,Shenglong Ye,Tsai-Sheng Yang,Jianming Xu,Yan Sun,Houjie Liang,Jiwei Liu,Jiejun Wang,Won Young Tak,Hongming Pan,Karin Burock,Jessie Zou,Dimitris Voliotis,Zhongzhen Guan.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial[J]. Lancet Oncology . 2009 (1)
  • 2Laura A.E. Hughes,Veerle Melotte,Joachim de Schrijver,Michiel de Maat,Vincent T.H.B.M. Smit,Judith V.M.G. Bovée,Pim J. French,Piet A. van den Brandt,Leo J. Schouten,Tim de Meyer,Wim van Criekinge,Nita Ahuja,James G. Herman,Matty P. Weijenberg,Manon van Engeland.The CpG Island Methylator Phenotype: What’s in a Name?[J]. Cancer Research . 2013 (19)
  • 3K. V. Menon,A. R. Hakeem,N. D. Heaton.Meta‐analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma[J]. Aliment Pharmacol Ther . 2012 (4)
  • 4Huanjie Shao,Chun Gao,Haikuo Tang,Hao Zhang,Lewis R. Roberts,Bonnie L. Hylander,Elizabeth A. Repasky,Wen W. Ma,Jingxin Qiu,Alex A. Adjei,Grace K. Dy,Chunrong Yu.Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo[J]. Journal of Hepatology . 2011 (1)
  • 5Ledu Zhou,Yun Huang,Jingdong Li,Zhiming Wang.The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma[J]. Medical Oncology . 2010 (2)
  • 6Timothy R. Peterson,Mathieu Laplante,Carson C. Thoreen,Yasemin Sancak,Seong A. Kang,W. Michael Kuehl,Nathanael S. Gray,David M. Sabatini.DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival[J]. Cell . 2009 (5)
  • 7Anthony P. Monaco.The Role of mTOR Inhibitors in the Management of Posttransplant Malignancy[J]. Transplantation . 2009 (2)
  • 8Timothy A Yap,Michelle D Garrett,Mike I Walton,Florence Raynaud,Johann S de Bono,Paul Workman.Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises[J]. Current Opinion in Pharmacology . 2008 (4)
  • 9SumioWatanabe,YasuoHorie,EiKataoka,WataruSato,TakahiroDohmen,ShigetoshiOhshima,TakashiGoto,AkiraSuzuki.Non‐alcoholic steatohepatitis and hepatocellular carcinoma: Lessons from hepatocyte‐specific phosphatase and tensin homolog (PTEN)‐deficient mice[J]. Journal of Gastroenterology and Hepatology . 2007
  • 10Christian Toso,Glenda A. Meeberg,David L. Bigam,Jose Oberholzer,A M. James Shapiro,Klaus Gutfreund,Mang M. Ma,Andrew L. Mason,Winnie W. S. Wong,Vincent G. Bain,Norman M. Kneteman.De Novo Sirolimus-Based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma: Long-Term Outcomes and Side Effects[J]. Transplantation . 2007 (9)

共引文献2

同被引文献4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部